Molecular, histopathological, and genomic variants of glioblastoma

Frontiers in Bioscience - Landmark

Volumn 19, Issue 7, 2014, Pages 1065-1087

  Karsy, Michael ^a   Huang, Tiangui ^b   Kleinman, George ^b   Karpel Massler, Georg ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

Expression Profile; GBM; Glioblastoma; Glioma; Review; Subtypes; Variant

Indexed keywords

BRAIN NEOPLASMS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; GLIOBLASTOMA; HUMAN; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; PROCEDURES;

BRAIN NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GLIOBLASTOMA; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION;

EID: 84904689011     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4268     Document Type: Article

References (197)

1. R Stupp, ME Hegi, WP Mason, MJ van den Bent, MJB Taphoorn, RC Janzer, SK Ludwin, A Allgeier, B Fisher, K Belanger, P Hau, AA Brandes, J Gijtenbeek, C Marosi, CJ Vecht, K Mokhtari, P Wesseling, S Villa, E Eisenhauer, T Gorlia, et al.: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10, 459-466 (2009)
2. ME Hegi, A-C Diserens, T Gorlia, M-F Hamou, N de Tribolet, M Weller, JM Kros, JA Hainfellner, W Mason, L Mariani, JEC Bromberg, P Hau, RO Mirimanoff, JG Cairncross, RC Janzer, R Stupp: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352, 997-1003 (2005) (Pubitemid 40349502)
3. DN Louis, HH Ohgaki, OD Wiestler, WK Cavenee: WHO Classification of Tumours of the Central Nervous System, 4th ed. WHO Press, Albany, NY, (2007)
4. H Ohgaki, P Kleihues: Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 28, 177-183 (2011)
5. G Fulci, N Ishii, D Maurici, KM Gernert, P Hainaut, B Kaur, EG Van Meir: Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion. Cancer Res 62, 2897-2905 (2002) (Pubitemid 34525777)
6. WB Pope, A Lai, P Nghiemphu, P Mischel, TF Cloughesy: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66, 1258-1260 (2006) (Pubitemid 43739717)
7. JT Huse, EC Holland: Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10, 319-331 (2010)
8. YP Ramirez, JL Weatherbee, RT Wheelhouse, AH Ross: Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals (Basel) 6, 1475-1506 (2013)
9. M Nagane, R Nishikawa: Bevacizumab for glioblastoma-a promising drug or not? Cancers (Basel) 5, 1456-1468 (2013)
10. O Bloch, SJ Han, S Cha, MZ Sun, MK Aghi, MW McDermott, MS Berger, AT Parsa: Impact of extent of resection for recurrent glioblastoma on overall survival. J Neurosurg 117, 1032-1038 (2012)
11. B Vogelstein, N Papadopoulos, VE Velculescu, S Zhou, LA Diaz, KW Kinzler: Cancer genome landscapes. Science 339, 1546-1558 (2013)
12. I Bozic, T Antal, H Ohtsuki, H Carter, D Kim, S Chen, R Karchin, KW Kinzler, B Vogelstein, MA Nowak: Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA 107, 18545-18550 (2010)
13. M Jhanwar-Uniyal, L Albert, E McKenna, M Karsy, P Rajdev, A Braun, R Murali: Deciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: role of Akt/mTOR and MAPK pathways. Adv Enzyme Regul 51, 164-170 (2011)
14. M Karsy, L Albert, ME Tobias, R Murali, M Jhanwar-Uniyal: All-trans retinoic acid modulates cancer stem cells of glioblastoma multiforme in an MAPK-dependent manner. Anticancer Res 30, 4915-4920 (2010)
15. EK-E Nduom, CG Hadjipanayis, EG Van Meir: Glioblastoma cancer stem-like cells: implications for pathogenesis and treatment. Cancer J 18, 100-106 (2012)
16. AJ Wong, JM Ruppert, SH Bigner, CH Grzeschik, PA Humphrey, DS Bigner, B Vogelstein: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89, 2965-2969 (1992)
17. H Ohgaki, P Kleihues. The definition of primary and secondary glioblastoma. Clin Can Res 19, 764-772 (2013).
18. AJ Ekstrand, N Sugawa, CD James, VP Collins: Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails. Proc Natl Acad Sci USA 89, 4309-4313 (1992)
19. N Sugawa, AJ Ekstrand, CD James, VP Collins: Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87, 8602-8606 (1990)
20. HS Huang, M Nagane, CK Klingbeil, H Lin, R Nishikawa, XD Ji, CM Huang, GN Gill, HS Wiley, WK Cavenee: The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272, 2927-2935 (1997) (Pubitemid 27053343)
21. L Frederick, XY Wang, G Eley, CD James: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60, 1383-1387 (2000) (Pubitemid 30152011)
22. W Biernat, H Huang, H Yokoo, P Kleihues, H Ohgaki: Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 14, 131-136 (2004) (Pubitemid 38656384)
23. AB Heimberger, R Hlatky, D Suki, D Yang, J Weinberg, M Gilbert, R Sawaya, K Aldape: Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11, 1462-1466 (2005) (Pubitemid 40315227)
24. Y Narita, M Nagane, K Mishima, H-JS Huang, FB Furnari, WK Cavenee: Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res 62, 6764-6769 (2002) (Pubitemid 35364149)
25. M-D-M Inda, R Bonavia, A Mukasa, Y Narita, DWY Sah, S Vandenberg, C Brennan, TG Johns, R Bachoo, P Hadwiger, P Tan, RA DePinho, W Cavenee, F: Furnari, Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 24, 1731-1745 (2010)
26. M-T Stockhausen, H Broholm, M Villingshøj, M Kirchhoff, T Gerdes, K Kristoffersen, M Kosteljanetz, M Spang-Thomsen, HS Poulsen: Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme. Exp Cell Res 317, 1513-1526 (2011)
27. G Karpel-Massler, CR Wirtz, M-E Halatsch: Drug combinations enhancing the antineoplastic effects of erlotinib in high-grade glioma. Recent Pat Anticancer Drug Discov 6, 384-394 (2011)
28. G Karpel-Massler, U Schmidt, A Unterberg, M-E Halatsch: Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand? Mol Cancer Res 7, 1000-1012 (2009)
29. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008)
30. PA Jänne: Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations. Sem Oncol 32, S9-15 (2005)
31. R Nishikawa, T Sugiyama, Y Narita, F Furnari, WK Cavenee, M Matsutani: Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathol 21, 53-56 (2004) (Pubitemid 39518146)
32. M Hermanson, K Funa, M Hartman, L Claesson-Welsh, CH Heldin, B Westermark, M Nistér: Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52, 3213-3219 (1992)
33. SV Sharma, DW Bell, J Settleman, DA Haber: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7, 169-181 (2007)
34. C Brennan, H Momota, D Hambardzumyan, T Ozawa, A Tandon, A Pedraza, E Holland: Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE 4, e7752 (2009)
35. HS Phillips, S Kharbanda, R Chen, WF Forrest, RH Soriano, TD Wu, A Misra, JM Nigro, H Colman, L Soroceanu, PM Williams, Z Modrusan, BG Feuerstein, K Aldape: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157-173 (2006) (Pubitemid 43357943)
36. T Ozawa, CW Brennan, L Wang, M Squatrito, T Sasayama, M Nakada, JT Huse, A Pedraza, S Utsuki, Y Yasui, A Tandon, EI Fomchenko, H Oka, RL Levine, K Fujii, M Ladanyi, EC Holland: PDGFRA gene rearrangements are frequent genetic events in PDGFRAamplified glioblastomas. Genes Dev 24, 2205-2218 (2010)
37. NJ Szerlip, A Pedraza, D Chakravarty, M Azim, J McGuire, Y Fang, T Ozawa, EC Holland, JT Huse, S Jhanwar, MA Leversha, T Mikkelsen, CW Brennan: Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci USA 109, 3041-3046 (2012)
38. B England, T Huang, M Karsy: Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol 34, 2063-2074 (2013)
39. G Reifenberger, L Liu, K Ichimura, EE Schmidt, VP Collins: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.. Cancer Res 53 2736-2739 (1993) (Pubitemid 23180507)
40. W Biernat, P Kleihues, Y Yonekawa, HH Ohgaki: Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56, 180-185 (1997) (Pubitemid 27461181)
41. M Nakamura, T Watanabe, U Klangby, C Asker, K Wiman, Y Yonekawa, P Kleihues, HH Ohgaki: p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11, 159-168 (2001) (Pubitemid 32198843)
42. A Petitjean, E Mathe, S Kato, C Ishioka, SV Tavtigian, P Hainaut, M Olivier: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28, 622-629 (2007) (Pubitemid 46744292)
43. JN Rich, C Hans, B Jones, ES Iversen, RE McLendon, BKA Rasheed, A Dobra, HK Dressman, DD Bigner, JR Nevins, M West: Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 65, 4051-4058 (2005) (Pubitemid 40775641)
44. C Houillier, J Lejeune, A Benouaich-Amiel, F Laigle-Donadey, E Criniere, K Mokhtari, J Thillet, J-Y Delattre, K Hoang-Xuan, M Sanson: Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 106, 2218-2223 (2006) (Pubitemid 43673244)
45. D Krex, B Klink, C Hartmann, A von Deimling, T Pietsch, M Simon, M Sabel, JP Steinbach, O Heese, G Reifenberger, M Weller, G Schackert, German Glioma Network: Long-term survival with glioblastoma multiforme. Brain 130, 2596-2606 (2007) (Pubitemid 47511715)
46. J Felsberg, M Rapp, S Loeser, R Fimmers, W Stummer, M Goeppert, H-J Steiger, B Friedensdorf, G Reifenberger, MC Sabel: Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 15, 6683-6693 (2009)
47. M Marutani, H Tonoki, M Tada, M Takahashi, H Kashiwazaki, Y Hida, J Hamada, M Asaka, T Moriuchi: Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. Cancer Res 59, 4765-4769 (1999) (Pubitemid 29472872)
48. T Soussi, G Lozano: p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 331, 834-842 (2005) (Pubitemid 40615514)
49. T Soussi, KG Wiman: Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12, 303-312 (2007) (Pubitemid 47539312)
50. GP Zambetti: The p53 mutation "gradient effect" and its clinical implications. J Cell Physiol 213, 370-373 (2007) (Pubitemid 47509715)
51. N Gulati, M Karsy, L Albert, R Murali, M Jhanwar-Uniyal: Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. Int J Oncol 35, 731-740 (2009)
52. D Koul: PTEN signaling pathways in glioblastoma. Cancer Biol Ther 7, 1321-1325 (2008)
53. A Sami, M Karsy: Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding. Tumour Biol 34, 1991-2002 (2013)
54. JR Molina, NK Agarwal, FC Morales, Y Hayashi, KD Aldape, G Cote, M-M Georgescu: PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene 31, 1264-1274 (2012)
55. IK Mellinghoff, MY Wang, I Vivanco, DA Haas-Kogan, S Zhu, EQ Dia, KV Lu, K Yoshimoto, JHY Huang, DJ Chute, BL Riggs, S Horvath, LM Liau, WK Cavenee, PN Rao, R Beroukhim, TC Peck, JC Lee, WR Sellers, D Stokoe, et al: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353, 2012-2024 (2005) (Pubitemid 41609094)
56. R Endersby, SJ Baker: PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene 27, 5416-5430 (2008)
57. L Albert, M Karsy, R Murali, M Jhanwar-Uniyal: Inhibition of mTOR activates the MAPK pathway in glioblastoma multiforme. Cancer Genomics Proteomics 6, 255-261 (2009)
58. D Kita, Y Yonekawa, M Weller, H Ohgaki: PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol 113, 295-302 (2007) (Pubitemid 46443564)
59. H Sasaki, MC Zlatescu, RA Betensky, Y Ino, JG Cairncross, DN Louis: PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 159, 359-367 (2001) (Pubitemid 33704221)
60. H Zheng, H Ying, H Yan, AC Kimmelman, DJ Hiller, A-J Chen, SR Perry, G Tonon, GC Chu, Z Ding, JM Stommel, KL Dunn, R Wiedemeyer, MJ You, C Brennan, YA Wang, KL Ligon, WH Wong, L Chin, RA DePinho: p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455, 1129-1133 (2008)
61. Y Wang, J Yang, H Zheng, GJ Tomasek, P Zhang, PE McKeever, EY-HP Lee, Y Zhu: Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell 15, 514-526 (2009)
62. SM Chang, P Wen, T Cloughesy, H Greenberg, D Schiff, C Conrad, K Fink, HI Robins, L De Angelis, J Raizer, K Hess, K Aldape, KR Lamborn, J Kuhn, J Dancey, MD Prados, North American Brain Tumor Consortium and the National Cancer Institute: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23, 357-361 (2005) (Pubitemid 40980358)
63. M Nakamura, Y Yonekawa, P Kleihues, H Ohgaki. Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest 81, 77-82 (2001) (Pubitemid 32108641)
64. G Reifenberger, J Reifenberger, K Ichimura, PS Meltzer, VP Collins: Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 54, 4299-4303 (1994) (Pubitemid 24273138)
65. JF Costello, C Plass, W Arap, VM Chapman, WA Held, MS Berger, HJ Su Huang, WK Cavenee: Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res 57, 1250-1254 (1997) (Pubitemid 27152546)
66. M Nakamura, F Yang, H Fujisawa, Y Yonekawa, P Kleihues, H Ohgaki: Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol 59, 539-543 (2000) (Pubitemid 30368313)
67. M Simon, D Voss, T-W Park-Simon, R Mahlberg, G Köster: Role of p16 and p14ARF in radio-and chemosensitivity of malignant gliomas. Oncol Rep 16, 127-132 (2006)
68. M Wager, P Menei, J Guilhot, P Levillain, S Michalak, B Bataille, J-L Blanc, F Lapierre, P Rigoard, S Milin, F Duthe, D Bonneau, C-J Larsen, L Karayan-Tapon: Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study. Br J Cancer 98, 1830-1838 (2008) (Pubitemid 351748843)
69. R Wiedemeyer, C Brennan, TP Heffernan, Y Xiao, J Mahoney, A Protopopov, H Zheng, G Bignell, F Furnari, WK Cavenee, WC Hahn, K Ichimura, VP Collins, GC Chu, MR Stratton, KL Ligon, PA Futreal, L Chin: Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell 13, 355-364 (2008) (Pubitemid 351454058)
70. M Nakamura, E Ishida, K Shimada, M Kishi, H Nakase, T Sakaki, N Konishi: Frequent LOH on 22q123 and TIMP-3 inactivation occur in the progression to secondary glioblastomas. Lab Invest 85, 165-175 (2005) (Pubitemid 40208920)
71. JG Cairncross, K Ueki, MC Zlatescu, DK Lisle, DM Finkelstein, RR Hammond, JS Silver, PC Stark, DR Macdonald, Y Ino, DA Ramsay, DN Louis: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90, 1473-1479 (1998) (Pubitemid 28482012)
72. GS Bauman, Y Ino, K Ueki, MC Zlatescu, BJ Fisher, DR Macdonald, L Stitt, DN Louis, JG Cairncross: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 48, 825-830 (2000)
73. J Felsberg, A Erkwoh, MC Sabel, L Kirsch, R Fimmers, B Blaschke, U Schlegel, J Schramm, OD Wiestler, G Reifenberger: Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 14, 121-130 (2004) (Pubitemid 38656383)
74. RB Jenkins, H Blair, KV Ballman, C Giannini, RM Arusell, M Law, H Flynn, S Passe, S Felten, PD Brown, EG Shaw, JC Buckner: A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66, 9852-9861 (2006) (Pubitemid 44672036)
75. T Homma, T Fukushima, S Vaccarella, Y Yonekawa, PL Di Patre, S Franceschi, H Ohgaki: Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 65, 846-854 (2006) (Pubitemid 44371230)
76. D Kaneshiro, T Kobayashi, ST Chao, J Suh, RA Prayson: Chromosome 1p and 19q deletions in glioblastoma multiforme. Appl Immunohistochem Mol Morphol 17, 512-516 (2009)
77. DW Parsons, S Jones, X Zhang, JC-H Lin, RJ Leary, P Angenendt, P Mankoo, H Carter, I-M Siu, GL Gallia, A Olivi, R McLendon, BA Rasheed, S Keir, T Nikolskaya, Y Nikolsky, DA Busam, H Tekleab, LA Diaz, J Hartigan, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008)
78. M Sanson, Y Marie, S Paris, A Idbaih, J Laffaire, F Ducray, S El Hallani, B Boisselier, K Mokhtari, K Hoang-Xuan, J-Y Delattre: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27, 4150-4154 (2009)
79. S Nobusawa, T Watanabe, P Kleihues, H Ohgaki: IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15, 6002-6007 (2009)
80. C Loenarz, CJ Schofield: Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol 4, 152-156 (2008) (Pubitemid 351264133)
81. B Pietrak, H Zhao, H Qi, C Quinn, E Gao, JG Boyer, N Concha, K Brown, C Duraiswami, R Wooster, S Sweitzer, B Schwartz: A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of aHG. Biochemistry 50, 4804-4812 (2011)
82. P Koivunen, S Lee, CG Duncan, G Lopez, G Lu, S Ramkissoon, JA Losman, P Joensuu, U Bergmann, S Gross, J Travins, S Weiss, R Looper, KL Ligon, RGW Verhaak, H Yan, WG Kaelin: Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483, 484-488 (2012)
83. H Noushmehr, DJ Weisenberger, K Diefes, HS Phillips, K Pujara, BP Berman, F Pan, CE Pelloski, EP Sulman, KP Bhat, RGW Verhaak, KA Hoadley, DN Hayes, CM Perou, HK Schmidt, L Ding, RK Wilson, D Van Den Berg, H Shen, H Bengtsson, et al: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510-522 (2010)
84. ME Figueroa, O Abdel-Wahab, C Lu, PS Ward, J Patel, A Shih, Y Li, N Bhagwat, A Vasanthakumar, HF Fernandez, MS Tallman, Z Sun, K Wolniak, JK Peeters, W Liu, SE Choe, VR Fantin, E Paietta, B Löwenberg, JD Licht, et al: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553-567 (2010)
85. W Xu, H Yang, Y Liu, Y Yang, P Wang, S-H Kim, S Ito, C Yang, P Wang, M-T Xiao, L-X Liu, W-Q Jiang, J Liu, J-Y Zhang, B Wang, S Frye, Y Zhang, Y-H Xu, Q-Y Lei, K-L Guan, et al: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell 19; 17-30 (2011)
86. H Yan, DW Parsons, G Jin, R McLendon, BA Rasheed, W Yuan, I Kos, I Batinic-Haberle, S Jones, GJ Riggins, H Friedman, A Friedman, D Reardon, J Herndon, KW Kinzler, VE Velculescu, B Vogelstein, DD Bigner: IDH1 and IDH2 mutations in gliomash. N Engl J Med 360, 765-773 (2009)
87. C Hartmann, B Hentschel, W Wick, D Capper, J Felsberg, M Simon, M Westphal, G Schackert, R Meyermann, T Pietsch, G Reifenberger, M Weller, M Loeffler, A von Deimling: Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120, 707-718 (2010)
88. A Lai, S Kharbanda, WB Pope, A Tran, OE Solis, F Peale, WF Forrest, K Pujara, JA Carrillo, A Pandita, BM Ellingson, CW Bowers, RH Soriano, NO Schmidt, S Mohan, WH Yong, S Seshagiri, Z Modrusan, Z Jiang, KD Aldape, et al: Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29, 4482-4490 (2011)
89. WB Pope, RM Prins, M Albert Thomas, R Nagarajan, KE Yen, MA Bittinger, N Salamon, AP Chou, WH Yong, H Soto, N Wilson, E Driggers, HG Jang, SM Su, DP Schenkein, A Lai, TF Cloughesy, HI Kornblum, H Wu, VR Fantin, et al: Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol 107, 197-205 (2012)
90. S Shafqat, ET Hedley-Whyte, JW Henson: Agedependent rate of anaplastic transformation in low-grade astrocytoma. Neurology 52, 867-869 (1999) (Pubitemid 29120202)
91. SJ Han, I Yang, BJ Ahn, JJ Otero, T Tihan, MW McDermott, MS Berger, MD Prados, AT Parsa: Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients. Cancer 116, 1358-1366 (2010)
92. V Jung, BF Romeike, W Henn, W Feiden, JR Moringlane, KD Zang, S Urbschat: Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells. J Neuropathol Exp Neurol 58, 993-999 (1999) (Pubitemid 29441927)
93. JR Shapiro, WK Yung, WR Shapiro: Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res 41, 2349-2359 (1981) (Pubitemid 11111441)
94. K Koga, T Todaka, M Morioka, J Hamada, Y Kai, S Yano, A Okamura, N Takakura, T Suda, Y Ushio: Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 61, 6248-6254 (2001) (Pubitemid 32762564)
95. M Karsy, M Gelbman, P Shah, O Balumbu, F Moy, E Arslan: Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features. Folia Neuropathol 50, 301-321 (2012)
96. P Bailey, H Cushing: A Classification of the tumors of the glioma group on a histogenetic basis with a correlated study of prognosis, JB Lippincott Co, Philadelphia, 1926
97. JW Kernohan, RF Mabon: A simplified classification of the gliomas Proc Staff Meet Mayo Clin 24, 71-75 (1949)
98. C Daumas-Duport, B Scheithauer, J O'Fallon, P Kelly: Grading of astrocytomas -A simple and reproducible method. Cancer 62, 2152-2165 (1988) (Pubitemid 18261854)
99. CR Miller, A Perry: Glioblastoma. Arch Pathol Lab Med 131, 397-406 (2007)
100. H Jones, PV Steart, RO Weller: Spindle-cell glioblastoma or gliosarcoma? Neuropathol Appl Neurobiol 17, 177-187 (1991)
101. PH Carstens, GS Johnson, LF Jelsma: Spinal gliosarcoma: a light, immunohistochemical and ultrastructural study. Ann Clin Lab Sci 25, 241-246 (1995)
102. JW Grant, PV Steart, A Aguzzi, DB Jones, PJ Gallagher: Gliosarcoma: an immunohistochemical study. Acta Neuropathol 79, 305-309 (1989) (Pubitemid 20017604)
103. JM Meis, KL Ho, JS Nelson: Gliosarcoma: a histologic and immunohistochemical reaffirmation. Mod Pathol 3, 19-24 (1990)
104. JT Rutka, JR Giblin, HK Høifødt, DV Dougherty, CW Bell, JR McCulloch, RL Davis, CB Wilson, ML Rosenblum: Establishment and characterization of a cell line from a human gliosarcoma. Cancer Res 46, 5893-5902 (1986) (Pubitemid 17178003)
105. JR Perry, LC Ang, JM Bilbao, PJ Muller: Clinicopathologic features of primary and postirradiation cerebral gliosarcoma. Cancer 75, 2910-2918 (1995)
106. D Lee, SY Kang, Y-L Suh, JY Jeong, J-I Lee, D-H Nam: Clinicopathologic and genomic features of gliosarcomas. J Neurooncol 107, 643-650 (2012)
107. RM Reis, D Könü-Lebleblicioglu, JM Lopes, P Kleihues, HH Ohgaki: Genetic profile of gliosarcomas. Am J Pathol 156, 425-432 (2000) (Pubitemid 30643797)
108. B Actor, JMJL Cobbers, R Büschges, M Wolter, CB Knobbe, P Lichter, G Reifenberger, RG Weber: Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Genes Chromosom Cancer 34, 416-427 (2002) (Pubitemid 34787463)
109. W Biernat, A Aguzzi, U Sure, JW Grant, P Kleihues, ME Hegi: Identical mutations of the p53 tumor suppressor gene in the gliomatous and the sarcomatous components of gliosarcomas suggest a common origin from glial cells. J Neuropathol Exp Neurol 54, 651-656 (1995)
110. RH Boerman, K Anderl, J Herath, T Borell, N Johnson, J Schaeffer-Klein, A Kirchhof, AK Raap, BW Scheithauer, RB Jenkins: The glial and mesenchymal elements of gliosarcomas share similar genetic alterations. J Neuropathol Exp Neurol 55, 973-981 (1996) (Pubitemid 126449411)
111. JA Ozolek, SD Finkelstein, ME Couce: Gliosarcoma with epithelial differentiation: immunohistochemical and molecular characterization A case report and review of the literature. Mod Pathol 17, 739-745 (2004) (Pubitemid 38715500)
112. L Palma, P Celli, A Maleci, N Di Lorenzo, G Cantore: Malignant monstrocellular brain tumours A study of 42 surgically treated cases. Acta Neurochir (Wien) 97, 17-25 (1989) (Pubitemid 19085465)
113. KR Kozak, JS Moody: Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis. Neuro-Oncology 11, 833-841 (2009)
114. N Shinojima, M Kochi, J-I Hamada, H Nakamura, S Yano, K Makino, H Tsuiki, K Tada, J-I Kuratsu, Y Ishimaru, Y Ushio: The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg 101, 219-226 (2004) (Pubitemid 38970996)
115. W Müller, F Slowik, R Firsching, D Afra, P Sanker: Contribution to the problem of giant cell astrocytomas. Neurosurg Rev 10, 213-219 (1987)
116. B Meyer-Puttlitz, Y Hayashi, A Waha, B Rollbrocker, J Boström, OD Wiestler, DN Louis, G Reifenberger, A von Deimling: Molecular genetic analysis of giant cell glioblastomas. Am J Pathol 151, 853-857 (1997) (Pubitemid 27385617)
117. R Martinez, W Roggendorf, G Baretton, R Klein, G Toedt, P Lichter, G Schackert, S Joos: Cytogenetic and molecular genetic analyses of giant cell glioblastoma multiforme reveal distinct profiles in giant cell and nongiant cell subpopulations. Cancer Genet Cytogenet 175, 26-34 (2007) (Pubitemid 46694001)
118. M Karremann, U Rausche, G Fleischhack, M Nathrath, T Pietsch, CM Kramm, JEA Wolff: Clinical and epidemiological characteristics of pediatric gliosarcomas. J Neurooncol 97, 257-265 (2010)
119. DG du Plessis, GS Rutherfoord, KA Joyce, C Walker: Phenotypic and genotypic characterization of glioblastoma multiforme with epithelial differentiation and adenoid formations. Clin Neuropathol 23, 141-148 (2004) (Pubitemid 38993047)
120. FJ Rodriguez, BW Scheithauer, C Giannini, SC Bryant, RB Jenkins: Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study. Cancer 113, 2779-2789 (2008)
121. LJ Lewis-Tuffin, F Rodriguez, C Giannini, B Scheithauer, BM Necela, JN Sarkaria, PZ Anastasiadis: Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS ONE 5, e13665 (2010)
122. R Neelima, CV Gopalakrishnan, B Thomas, VV Radhakrishnan: Glioblastoma multiforme with epithelial differentiation. Neurol India 59, 918-920 (2011)
123. PC Burger, DK Pearl, K Aldape, AJ Yates, BW Scheithauer, SM Passe, RB Jenkins, CD James: Small cell architecture: a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol 60, 1099-1104 (2001) (Pubitemid 33021443)
124. A Perry, KD Aldape, DH George, PC Burger: Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer 101, 2318-2326 (2004) (Pubitemid 39458690)
125. M Quezado, R Ronchetti, A Rapkiewicz, M Santi, DT Blumenthal, EJ Rushing: Chromogenic in situ hybridization accurately identifies EGFR amplification in small cell glioblastoma multiforme, a common subtype of primary GBM. Clin Neuropathol 24, 163-169 (2005) (Pubitemid 40961500)
126. D Vordermark, K Ruprecht, P Rieckmann, W Roggendorf, GH Vince, M Warmuth-Metz, O Kölbl, M Flentje: Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after postoperative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). BMC Cancer 6, 247 (2006)
127. M Salvati, AI Formichella, A D'Elia, C Brogna, A Frati, F Giangaspero, R Delfini, A Santoro: Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases. J Neurooncol 94, 129-134 (2009)
128. T Nagasaka, M Gunji, N Hosokai, K Hayashi, H Ikeda, M Ito, S Inao: FISH 1p/19q deletion/imbalance for molecular subclassification of glioblastoma. Brain Tumor Pathol 24, 1-5 (2007) (Pubitemid 46836348)
129. LW Pinto, MBM Araújo, AL Vettore, L Wernersbach, ACC Leite, LMC Chimelli, FA Soares: Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis. Virchows Arch 452, 481-490 (2008)
130. B Klink, B Schlingelhof, M Klink, K Stout-Weider, S Patt, E Schrock: Glioblastomas with oligodendroglial component-common origin of the different histological parts and genetic subclassification. Cell Oncol (Dordr) 34, 261-275 (2011)
131. Y Wang, S Li, L Chen, G You, Z Bao, W Yan, Z Shi, Y Chen, K Yao, W Zhang, C Kang, T Jiang: Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro-Oncology 14, 518-525 (2012)
132. ME Hegi, R-C Janzer, WL Lambiv, T Gorlia, MCM Kouwenhoven, C Hartmann, A von Deimling, D Martinet, N Besuchet Schmutz, A-C Diserens, M-F Hamou, P Bady, M Weller, MJ van den Bent, WP Mason, R-O Mirimanoff, R Stupp, K Mokhtari, P Wesseling: Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC-26981/NCIC-CE3 trial. Acta Neuropathol 123, 841-852 (2012)
133. SY Ha, SY Kang, I-G Do, Y-L Suh: Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age. J Neurooncol 112, 439-448 (2013)
134. A Perry, CR Miller, M Gujrati, BW Scheithauer, SC Zambrano, SC Jost, R Raghavan, J Qian, EJ Cochran, JT Huse, EC Holland, PC Burger, MK Rosenblum: Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathol 19, 81-90 (2009)
135. P Varlet, D Soni, C Miquel, F-X Roux, J-F Meder, H Chneiweiss, C Daumas-Duport: New variants of malignant glioneuronal tumors: a clinicopathological study of 40 cases. Neurosurgery 55, 1377-1391 (2004) (Pubitemid 39612887)
136. H Takeuchi, T Hosoda, R Kitai, T Kodera, H Arishima, K Tsunetoshi, H Neishi, T Yamauchi, K Sato, Y Imamura, H Itoh, T Kubota, K-I Kikuta: Glioblastoma with oligodendroglial components: glioblastoma or anaplastic oligodendroglial tumors. Brain Tumor Pathol 29, 154-159 (2012)
137. JA Kraus, J Felsberg, JC Tonn, G Reifenberger, T Pietsch: Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood. Neuropathol Appl Neurobiol 28, 325-333 (2002) (Pubitemid 34989295)
138. HG Krouwer, RL Davis, P Silver, M Prados: Gemistocytic astrocytomas: a reappraisal. J Neurosurg 74, 399-406 (1991)
139. T Tihan, P Vohra, MS Berger, GE Keles: Definition and diagnostic implications of gemistocytic astrocytomas: a pathological perspective. J Neurooncol 76, 175-183 (2006) (Pubitemid 43125746)
140. MA Heesters, J Koudstaal, KG Go, WM Molenaar: Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value. J Neurooncol 44, 255-266 (1999) (Pubitemid 30113525)
141. DC Martins, SM Malheiros, LH Santiago, JN Stávale Gemistocytes in astrocytomas: are they a significant prognostic factor? J Neurooncol 80, 49-55 (2006) (Pubitemid 44473261)
142. K Watanabe, O Tachibana, Y Yonekawa, P Kleihues, H Ohgaki: Role of gemistocytes in astrocytoma progression. Lab Invest 76, 277-284 (1997) (Pubitemid 27082071)
143. JM Kros, N Waarsenburg, DP Hayes, WC Hop, H van Dekken: Cytogenetic analysis of gemistocytic cells in gliomas. J Neuropathol Exp Neurol 59, 679-686 (2000) (Pubitemid 30626738)
144. K Watanabe, A Peraud, C Gratas, S Wakai, P Kleihues, HH Ohgaki: p53 and PTEN gene mutations in gemistocytic astrocytomas. Acta Neuropathol 95, 559-564 (1998)
145. WR Markesbery, PE Duffy, D Cowen: Granular cell tumors of the central nervous system. J Neuropathol Exp Neurol 32, 92-109 (1973)
146. CH Rickert, W Paulus: Genetic characterisation of granular cell tumours. Acta Neuropathol 103, 309-312 (2002) (Pubitemid 36097024)
147. Y Shi, N Morgenstern: Granular cell astrocytoma. Arch Pathol Lab Med 132, 1946-1950 (2008)
148. J Schittenhelm, T Psaras: Glioblastoma with granular cell astrocytoma features: a case report and literature review. Clin Neuropathol 29, 323-329 (2010)
149. DJ Brat, BW Scheithauer, R Medina-Flores, MK Rosenblum, PC Burger: Infiltrative astrocytomas with granular cell features (granular cell astrocytomas): a study of histopathologic features, grading, and outcome. Am J Surg Pathol 26, 750-757 (2002) (Pubitemid 34546940)
150. AA Castellano-Sanchez, H Ohgaki, H Yokoo, BW Scheithauer, PC Burger, RL Hamilton, SD Finkelstein, DJ Brat: Granular cell astrocytomas show a high frequency of allelic loss but are not a genetically defined subset. Brain Pathol 13, 185-194 (2003) (Pubitemid 36460819)
151. M Joo, S-H Park, SH Chang, H Kim, C-Y Choi, C-H Lee, BH Lee, YJ Hwang: Cytogenetic and molecular genetic study on granular cell glioblastoma: a case report. Hum Pathol. 44, 282-288 (2013).
152. TJ MacDonald, D Aguilera, CM Kramm: Treatment of high-grade glioma in children and adolescents. Neuro-Oncology 13, 1049-1058 (2011)
153. I Qaddoumi, I Sultan, A Gajjar: Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database. Cancer 115, 5761-5770 (2009)
154. IF Pollack, SD Finkelstein, J Woods, J Burnham, EJ Holmes, RL Hamilton, AJ Yates, JM Boyett, JL Finlay, R Sposto, Children's Cancer Group: Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 346, 420-427 (2002) (Pubitemid 34437697)
155. C Hartmann, J Meyer, J Balss, D Capper, W Mueller, A Christians, J Felsberg, M Wolter, C Mawrin, W Wick, M Weller, C Herold-Mende, A Unterberg, JWM Jeuken, P Wesseling, G Reifenberger, A von Deimling: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118, 469-474 (2009)
156. IF Pollack, RL Hamilton, RW Sobol, J Burnham, AJ Yates, EJ Holmes, T Zhou, JL Finlay: O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol 24, 3431-3437, (2006) (Pubitemid 46638900)
157. IF Pollack, RL Hamilton, CD James, SD Finkelstein, J Burnham, AJ Yates, EJ Holmes, T Zhou, JL Finlay, Children's Oncology Group: Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg 105, 418-424 (2006) (Pubitemid 44954773)
158. D Faury, A Nantel, SE Dunn, M-C Guiot, T Haque, P Hauser, M Garami, L Bognar, Z Hanzély, PP Liberski, E Lopez-Aguilar, ET Valera, LG Tone, A-S Carret, RF Del Maestro, M Gleave, J-L Montes, T Pietsch, S Albrecht, N Jabado: Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 25, 1196-1208 (2007) (Pubitemid 46640565)
159. IF Pollack, RL Hamilton, PC Burger, DJ Brat, MK Rosenblum, GH Murdoch, MN Nikiforova, EJ Holmes, T Zhou, KJ Cohen, RI Jakacki, Children's Oncology Group: Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group. J Neurooncol 99, 155-163 (2010)
160. BS Paugh, A Broniscer, C Qu, CP Miller, J Zhang, RG Tatevossian, JM Olson, JR Geyer, SN Chi, NS da Silva, A Onar-Thomas, JN Baker, A Gajjar, DW Ellison, SJ Baker: Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol 29, 3999-4006 (2011)
161. JD Schiffman, JG Hodgson, SR Vandenberg, P Flaherty, M-YC Polley, M Yu, PG Fisher, DH Rowitch, JM Ford, MS Berger, H Ji, DH Gutmann, CD James: Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytoma. Cancer Res 70, 512-519 (2010)
162. T Huang, M Karsy, J Zhuge, M Zhong, D Liu: B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol 6, 30 (2013)
163. BS Paugh, C Qu, C Jones, Z Liu, M Adamowicz-Brice, J Zhang, DA Bax, B Coyle, J Barrow, D Hargrave, J Lowe, A Gajjar, W Zhao, A Broniscer, DW Ellison, RG Grundy, SJ Baker: Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28, 3061-3068 (2010)
164. J Schwartzentruber, A Korshunov, X-Y Liu, DTW Jones, E Pfaff, K Jacob, D Sturm, AM Fontebasso, D-AK Quang, M Tönjes, V Hovestadt, S Albrecht, M Kool, A Nantel, C Konermann, A Lindroth, N Jäger, T Rausch, M Ryzhova, JO Korbel, et al: Driver mutations in histone H33 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226-231 (2012)
165. CL Nutt, DR Mani, RA Betensky, P Tamayo, JG Cairncross, C Ladd, U Pohl, C Hartmann, ME McLaughlin, TT Batchelor, PM Black, A von Deimling, SL Pomeroy, TR Golub, DN Louis: Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63, 1602-1607 (2003) (Pubitemid 36373650)
166. M Shirahata, K Iwao-Koizumi, S Saito, N Ueno, M Oda, N Hashimoto, JA Takahashi, K Kato: Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis. Clin Cancer Res 13, 7341-7356 (2007)
167. Y Lee, AC Scheck, TF Cloughesy, A Lai, J Dong, HK Farooqi, LM Liau, S Horvath, PS Mischel, SF Nelson: Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics 1, 52 (2008)
168. M Vitucci, DN Hayes, CR Miller: Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br J Cancer 104, 545-553 (2011)
169. M Esteller, J Garcia-Foncillas, E Andion, SN Goodman, OF Hidalgo, V Vanaclocha, SB Baylin, JG Herman: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343, 1350-1354 (2000)
170. V Frattini, V Trifonov, JM Chan, A Castano, M Lia, F Abate, ST Keir, AX Ji, P Zoppoli, F Niola, C Danussi, I Dolgalev, P Porrati, S Pellegatta, A Heguy, G Gupta, DJ Pisapia, P Canoll, JN Bruce, RE McLendon, et al: The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 45, 1141-1149 (2013)
171. RGW Verhaak, KA Hoadley, E Purdom, V Wang, Y Qi, MD Wilkerson, CR Miller, L Ding, T Golub, JP Mesirov, G Alexe, M Lawrence, M O'Kelly, P Tamayo, BA Weir, S Gabriel, W Winckler, S Gupta, L Jakkula, HS Feiler, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010)
172. H Zarkoob, JH Taube, SK Singh, SA Mani, M Kohandel: Investigating the link between molecular subtypes of glioblastoma, epithelial-mesenchymal transition, and CD133 cell surface protein. PLoS ONE 8, e64169 (2013)
173. KPL Bhat, V Balasubramaniyan, B Vaillant, R Ezhilarasan, K Hummelink, F Hollingsworth, K Wani, L Heathcock, JD James, LD Goodman, S Conroy, L Long, N Lelic, S Wang, J Gumin, D Raj, Y Kodama, A Raghunathan, A Olar, K Joshi, et al: Mesenchymal differentiation mediated by NF-?B promotes radiation resistance in glioblastoma. Cancer Cell 24, 331-346 (2013)
174. WS Lee, EY Woo, J Kwon, M-J Park, J-S Lee, Y-H Han, IH Bae: Bcl-w Enhances Mesenchymal Changes and Invasiveness of Glioblastoma Cells by Inducing Nuclear Accumulation of ß-Catenin. PLoS ONE 8, e68030 (2013)
175. PC Burger, BW Scheithauer, FS Vogel: Surgical Pathology of the Nervous System and its Coverings. 4th ed. Churchill Livingstone, New York, NY (2002)
176. H Colman, K Aldape: Molecular predictors in glioblastoma: toward personalized therapy. Arch Neurol 65, 877-883 (2008) (Pubitemid 352008470)
177. K Hayashi, N Ohara, HJ Jeon, S Akagi, K Takahashi, T Akagi, S Namba: Gliosarcoma with features of chondroblastic osteosarcoma. Cancer 72, 850-855 (1993) (Pubitemid 23215275)
178. T Hoshino, BC Wilson, WG Ellis: Gemistocytic astrocytes in gliomas. An autoradiographic study. J Neuropathol Exp Neurol 34, 263-281 (1975)
179. M Nagaishi, Y-H Kim, M Mittelbronn, F Giangaspero, W Paulus, B Brokinkel, A Vital, Y Tanaka, Y Nakazato, C Legras-Lachuer, J Lachuer, H Ohgaki: Amplification of the STOML3, FREM2, and LHFP genes is associated with mesenchymal differentiation in gliosarcoma. Am J Pathol 180, 1816-1823 (2012)
180. M Nagaishi, W Paulus, B Brokinkel, A Vital, Y Tanaka, Y Nakazato, F Giangaspero, H Ohgaki: Transcriptional factors for epithelial-mesenchymal transition are associated with mesenchymal differentiation in gliosarcoma. Brain Pathol 22, 670-676 (2012)
181. WH Brooks, WR Markesbery, GD Gupta, TL Roszman: Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol 4, 219-224 (1978) (Pubitemid 8389815)
182. K Donev, BW Scheithauer, FJ Rodriguez, S Jenkins: Expression of diagnostic neuronal markers and outcome in glioblastoma. Neuropathol Appl Neurobiol 36, 411-421 (2010)
183. A Peraud, K Watanabe, K Schwechheimer, Y Yonekawa, P Kleihues, H Ohgaki: Genetic profile of the giant cell glioblastoma. Lab Invest 79, 123-129 (1999) (Pubitemid 29110643)
184. ML Simmons, KR Lamborn, M Takahashi, P Chen, MA Israel, MS Berger, T Godfrey, J Nigro, M Prados, S Chang, FG Barker, K Aldape: Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61, 1122-1128 (2001) (Pubitemid 32174434)
185. JJ Kepes, KH Fulling, JH Garcia: The clinical significance of "adenoid" formations of neoplastic astrocytes, imitating metastatic carcinoma, in gliosarcomas: A review of five cases. Clin Neuropathol 1, 139-150 (1982) (Pubitemid 13081339)
186. W Mueller, U Lass, J Herms, K Kuchelmeister, M Bergmann, A von Deimling: Clonal analysis in glioblastoma with epithelial differentiation. Brain Pathol 11, 39-43 (2001)
187. SJ Mørk, LJ Rubinstein, JJ Kepes, E Perentes, DF Uphoff: Patterns of epithelial metaplasia in malignant gliomas II Squamous differentiation of epithelial-like formations in gliosarcomas and glioblastomas. J Neuropathol Exp Neurol 47, 101-118 (1988) (Pubitemid 18087767)
188. P Metellus, I Nanni-Metellus, C Delfino, C Colin, A Tchogandjian, B Coulibaly, F Fina, A Loundou, M Barrie, O Chinot, L Ouafik, D Figarella-Branger: Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. Ann Surg Oncol 18, 2937-2945 (2011)
189. K Motomura, A Natsume, R Watanabe, I Ito, Y Kato, H Momota, R Nishikawa, K Mishima, Y Nakasu, T Abe, H Namba, Y Nakazato, H Tashiro, I Takeuchi, T Mori, T Wakabayashi: Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas. Cancer Sci (2012)
190. H Quon, B Abdulkarim: Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev 16, CD007104 (2008)
191. C Sarkar, MC Sharma, K Sudha, S Gaikwad, A Varma: A clinico-pathological study of 29 cases of gliosarcoma with special reference to two unique variants. Indian J Med Res 106, 229-235 (1997) (Pubitemid 27450259)
192. SF Smith, JM Simpson, JA Brewer, LHS Sekhon, MT Biggs, RJ Cook, NS Little: The presence of necrosis and/or microvascular proliferation does not influence survival of patients with anaplastic oligodendroglial tumours: review of 98 patients. J Neurooncol 80; 75-82 (2006) (Pubitemid 44473265)
193. NO Kandemir, B Bahadir, S Gul, N Karadayi, SO Ozdamar: Glioblastoma with primitive neuroectodermal tumor-like features: case report. Turk Neurosurg 19, 260-264 (2009)
194. A Karina, BP Jonker, A Morey, C Selinger, R Gupta, ME Buckland: Glioblastoma with primitive neuroectodermal tumour-like components. Pathology 44; 270-273 (2012)
195. S Avninder, MC Sharma, P Deb, VS Mehta, AK Karak, AK Mahapatra, C Sarkar: Gemistocytic astrocytomas: histomorphology, proliferative potential and genetic alterations-a study of 32 cases. J Neurooncol 78; 123-127 (2006) (Pubitemid 44339679)
196. RM Reis, A Hara, P Kleihues, H Ohgaki: Genetic evidence of the neoplastic nature of gemistocytes in astrocytomas. Acta Neuropathol 102, 422-425 (2001) (Pubitemid 32976074)
197. AH Stegh, H Kim, RM Bachoo, KL Forloney, J Zhang, H Schulze, K Park, GJ Hannon, J Yuan, DN Louis, RA DePinho, L Chin: Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 21, 98-111 (2007) (Pubitemid 46089711)